Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H1/00—Processes for the preparation of sugar derivatives
  • C07H1/06—Separation; Purification
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
  • B01D15/08—Selective adsorption, e.g. chromatography
  • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
  • B01D15/30—Partition chromatography
  • B01D15/305—Hydrophilic interaction chromatography [HILIC]
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
  • B01D15/08—Selective adsorption, e.g. chromatography
  • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
  • B01D15/32—Bonded phase chromatography
  • B01D15/325—Reversed phase
  • B01D15/327—Reversed phase with hydrophobic interaction
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01D—SEPARATION
  • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
  • B01D15/08—Selective adsorption, e.g. chromatography
  • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
  • B01D15/424—Elution mode
  • B01D15/426—Specific type of solvent
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H1/00—Processes for the preparation of sugar derivatives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Definitions

• Oligonucleotides are short DNA or RNA oligomers that can be chemically
• rp-HPLC reverse-phase high pressure liquid chromatography
• rp-HPLC reverse-phase high pressure liquid chromatography
• the invention herein describes a method to purify a target oligonucleotide using hydrophobic interaction chromatography (HIC).
• the method described herein includes applying, at a particular dynamic loading capacity, a mixture of the target oligonucleotide and product-related impurities to the hydrophobic interaction
• the claimed method can also remove the ABasic, the CNEt and/or the N+l impurities.
• FIG. 2 is a plot depicting the relationship between dynamic loading capacity and removal of the N-l impurity.
• the present invention is directed to methods for separating an oligonucleotide from a product related impurities generated during the synthesis of the oligonucleotide.
• the claimed method can also remove the ABasic impurities, the CNEt impurities and the N+l impurities that are difficult to be removed by rp-HPLC.
• oligonucleotide from a mixture containing the target oligonucleotide and a product-related impurity, the method comprising the steps of:
• the product-related impurity includes at least one N-l impurity, thereby separating the target oligonucleotide from the product-related impurity.
• a second embodiment of the invention is a method for separating a target oligonucleotide from a mixture containing the target thiolated oligonucleotide and a product- related impurity, the method comprising the steps of:
• a product-related impurity refers to the unwanted byproducts generated during the synthesis of the target oligonucleotide.
• N-l impurity is an oligonucleotide that is missing 1 nucleoside at any position relative to the target
• the product-related impurities can also include an ABasic impurity, a CNEt and/or a N+l impurities.
• a "N+l impurity” is an oligonucleotide that has 1 additional nucleoside at any position relative to the target oligonucleotide.
• an "ABasic impurity” is an oligonucleotide having one or more nucleosides that are missing the nucleobase as compared to the target oligonucleotide, wherein the nucleoside has the structure shown below:
• an exemplary structure for an ABasic impurity is shown in FIG. 3.
• the missing nucleobase in the ABasic impurity is adenosine and/or guanine.
• a "CNEt" impurity is an oligonucleotide that contains a modified thymine nucleobase in place of the unmodified thymine nucleobase of the target oligonucleotide, wherein the modified thymine nucleobase has the following structure:
• FIG. 3 An exemplary structure for CNEt impurity is shown in FIG. 3.
• the product-related impurities includes a shortmer impurity.
• a shortmer impurity is an oligonucleotide that is missing 1, 2, 3, 4, or more nucleosides at any position relative to the target oligonucleotide.
• the product-related impurities includes an earlier-eluting impurity (EEI).
• EAI earlier-eluting impurity
• the "earlier-elution impurity” is an impurity that elutes before the target oligonucleotide using the purification methods described herein.
• the product-related impuritiy includes a later-eluting impurity (LEI).
• LKI later-eluting impurity
• the "later-eluting impurity” is an impurity that elutes after the target oligonucleotide using the purification methods described herein.
• the LEI includes the N+l impurity.
• oligonucleotide means a compound comprising a plurality of linked nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or deoxyribonucleosides (DNA). In certain embodiments, the oligonucleotide includes only RNA, only DNA or includes both RNA and DNA. In a particular embodiment, the target oligonucleotide is a gapmer.
• a “gapmer” means a chimeric compound in which an internal region having a plurality of nucleosides that support RNase H cleavage is positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions.
• the target oligonucleotide comprises 10 to 100, 10 to 50, 10 to 25, 15 to 100, 15 to 50, or 15 to 25 nucleotides.
• Nucleoside means a compound comprising a nucleobase and a sugar moiety.
• Nucleosides include, but are not limited to, naturally occurring nucleosides, modified nucleosides, and nucleosides having mimetic bases and/or sugar groups.
• “Modified nucleoside” a nucleoside comprising at least one modification compared to naturally occurring RNA or DNA nucleosides. Such modification may be at the sugar moiety and/or at the nucleobase. Nucleosides may be modified with any of a variety of substituents on either the nucleobase or the sugar moiety.
• nucleotide refers to a nucleoside comprising a linking group, which links two nucleosides together as part of the oligonucleotide.
• the two main classes of linking groups are defined by the presence or absence of a phosphorus atom.
• Non- phosphorus containing linking groups include, but are not limited to, methylenemethylimino (— CH 2 -N(CH 3 )-0— CH 2 -), thiodiester (— O— C(O)— S— ), thionocarbamate (— O—
• nucleobase means the heterocyclic base portion of a nucleoside.
• a nucleobase may comprise any atom or group of atoms capable of hydrogen bonding to a nucleobase of another nucleic acid. Nucleobases may be naturally occurring or may be modified.
• nucleobases such as the purine nucleobases adenine (A) and guanine (G), and the pyrimidine nucleobases thymine (T) (or 5- methyl uracil), cytosine (C) and uracil (U)
• A purine nucleobase
• G guanine
• T pyrimidine nucleobase
• T thymine
• C cytosine
• U uracil
• nucleobase mimetic s known to those skilled in the art are amenable to incorporation into the target oligonucleotides as separated by either the method described in the first or second
• the method is as described for the first or second embodiment, and the nucleobase is selected from adenine, guanine, thymine (5-methyl uracil), and 5- methylcytosine.
• “Sugar moiety” means a natural or modified sugar or sugar surrogate.
• Natural sugar means a ribofuranose moiety of DNA (2'-H) or RNA (2'-OH).
• the sugar is modified at the 2'-position to include a substituent other than H or OH ("2 '-modified" or "2'-substituted”). Alternatively, the modification is at the 5'-position of the sugar. In certain embodiments, the sugar is modified at the 2'-position and the 5 '-position of the sugar.
• sugar modifications useful in this invention include, but are not limited to compounds comprising a sugar substituent group selected from: OH, F, O-alkyl, S-alkyl, N-alkyl, or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted CI to CIO alkyl or C2 to CIO alkenyl and alkynyl.
• a halide including, but not limited to F
• allyl amino, azido, thio, O-allyl, O—Ci-Cio alkyl,— OCF 3 , O— (CH 2 ) 2 — O— CH 3 , 2'- 0(CH 2 ) 2 SCH 3
• modified nucleosides suitable for use in the methods described in the first and second embodiments are: 2'-methoxyethoxy ("MOE” or “2'-MOE” or “2'-OCH 2 CH 2 OCH 3 ), 2'-0- methyl ("2'-OMe” or 2'-0— CH 3 ), or 2'-fluoro (2'-F).
• 2'-sugar substituent groups include: Ci to Qo alkyl, substituted alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, CI, Br, CN, CF 3 , OCF 3 , SOCH 3 , S0 2 CH 3 , ON0 2 , N0 2 , N 3 , NH 2 , heterocyclyl, and aminoalkylamino.
• modified nucleosides having a substituent group at oxygen atom at the 5'-position selected from acetyl (Ac); benzoyl (Bz); benzyl (Bn); ⁇ - methoxyethoxymethyl ether (MEM); dimethoxytrityl, [bis-(4-methoxyphenyl)phenylmethyl] (DMT); methoxymethyl ether (MOM); methoxytrityl [(4-methoxyphenyl)diphenylmethyl, MMT); p-methoxybenzyl ether (PMB); methylthiomethyl ether; pivaloyl (Piv);
• tetrahydropyranyl THP
• THF tetrahydrofuran
• Tr trityl
• silyl ether including, but not limited to, trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tri-iso- propylsilyloxymethyl (TOM), and triisopropylsilyl (TIPS) ethers
• TMS trimethylsilyl
• TDMS tert-butyldimethylsilyl
• TOM tri-iso- propylsilyloxymethyl
• TIPS triisopropylsilyl
• the 5' position is -ODMT.
• nucleosides having modified sugar moieties include without limitation nucleosides comprising 5'-vinyl, 5'-methyl, 5'-ODMT, 4'-S, 2'-F, 2'-OCH 3 and 2'- 0(CH 2 ) 2 OCH 3 substituent groups.
• 2'-sugar substituent groups are in either the arabino (up) position or ribo (down) position.
• a 2'-arabino modification is 2'-F arabino (FANA). Similar modifications can also be made at other positions on the sugar, particularly the 3' position of the sugar on a 3' terminal nucleoside or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.
• alkyl refers to a fully saturated branched or unbranched hydrocarbon moiety.
• the alkyl comprises 1 to 20 carbon atoms, more preferably 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms.
• an alkyl comprises from 6 to 20 carbon atoms.
• alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, or n-decyl.
• Alkenyl refers to an unsaturated hydrocarbon group which may be linear or branched and has at least one carbon-carbon double bond. Alkenyl groups with 2-6 carbon atoms can be preferred. The alkenyl group may contain 1, 2 or 3 carbon-carbon double bonds, or more. Examples of alkenyl groups include ethenyl, n-propenyl, isopropenyl, n-but-2-enyl, n-hex-3-enyl and the like. "Alkynyl” refers to an unsaturated hydrocarbon group which may be linear or branched and has at least one carbon-carbon triple bond. Alkynyl groups with 2-6 carbon atoms can be preferred.
• the alkynyl group may contain 1, 2 or 3 carbon-carbon triple bonds, or more.
• alkynyl groups include ethynyl, n-propynyl, n-but-2-ynyl, n-hex-3-ynyl and the like.
• aryl refers to monocyclic, bicyclic or tricyclic aromatic hydrocarbon groups having from 6 to 14 carbon atoms in the ring portion. In one embodiment, the term aryl refers to monocyclic and bicyclic aromatic hydrocarbon groups having from 6 to 10 carbon atoms. Representative examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthracenyl. The term “aryl” also refers to a bicyclic or tricyclic group in which at least one ring is aromatic and is fused to one or two non-aromatic hydrocarbon ring(s).
• Nonlimiting examples include tetrahydronaphthalene, dihydronaphthalenyl and indanyl.
• An "arylalkyl” is a aryl group linked via an alkylene linker to the reminder of the molecule.
• An “alkaryl” is a alkyl group linked via an arylene linker to the reminder of the molecule.
• heterocyclyl refers to a saturated or unsaturated, monocyclic or bicyclic (e.g., bridged or spiro ring systems) ring system which has from 3- to 7-ring members, or in particular 3- to 6- ring members or 5- to 7- ring members, at least one of which is a heteroatom, and up to 4 (e.g., 1, 2, 3, or 4) of which may be heteroatoms, wherein the heteroatoms are independently selected from O, S and N, and wherein C can be oxidized (e.g., C(O)), N can be oxidized (e.g., N(O)) or quaternized, and S can be optionally oxidized to sulfoxide and sulfone.
• C can be oxidized
• N can be oxidized
• S can be optionally oxidized to sulfoxide and sulfone.
• heteroaryl refers to an aromatic 5 or 6 membered monocyclic ring system, having 1 to 4 heteroatoms independently selected from O, S and N, and wherein N can be oxidized (e.g., N(O)) or quaternized, and S can be optionally oxidized to sulfoxide and sulfone.
• a heterocyclyl is a 3-to 7-membered saturated monocyclic or a 3-to 6-membered saturated monocyclic or a 5-to 7-membered saturated monocyclic ring.
• a heterocyclyl is a 3-to 7-membered monocyclic or a 3-to 6-membered monocyclic or a 5-to 7-membered monocyclic ring.
• a heterocyclyl is a 6 or-7-membered bicyclic ring.
• the heterocyclyl group can be attached at a heteroatom or a carbon atom.
• BNA Bicyclic nucleoside
• BNA a nucleoside wherein the sugar moiety of the nucleoside comprises a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic sugar moiety.
• BNAs include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms ("4'-2' bicyclic nucleoside”), for example, a furanose ring comprising a bridge connecting two carbon atoms of the furanose ring to connect the 2' carbon atom and the 4' carbon atom of the sugar ring.
• the target oligonucleotide includes one or more BNA nucleosides wherein the bridge comprises one of the formulas: 4'-P-D-(CH 2 )— 0-2' ( ⁇ -D- LNA); 4'-(CH 2 )— S-2; 4'-a-L-(CH 2 )— 0-2' (a-L-LNA); 4'-(CH 2 ) 2 — 0-2' (ENA); 4'- C(CH 3 ) 2 — 0-2' (see PCT/US2008/068922); 4'-CH(CH 3 )— 0-2' ("cEt") and 4'-C—
• N(OCH 3 )-2' see PCT/US2008/064591
• 4'-CH 2 — O— N(CH 3 )-2' see published U.S. Patent Application US2004-0171570, published Sep. 2, 2004
• 4'-CH 2 — N(R)— 0-2' see U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008
• R is, independently, H, CrC 12 alkyl, or a protecting group.
• the present invention provides modified nucleosides comprising modified sugar moieties that are not bicyclic sugar moieties.
• sugar surrogate means a structure other than a ribofuranose ring which is capable of substituting for the sugar of a nucleoside.
• sugar surrogates include, but are not limited to, 6-membered rings, sugars in which the oxygen is replaced with, for example, sulfur or nitrogen, to form, for example, morpholinos and 4'-thio-containing sugars.
• the target oligonucleotide separated by the method as described in either the first or second embodiment is a phosphorothioate oligonucleotide having a sequence of (from 5' to 3')
• TCACTTTCATAATGCTGG (SEQ ID NO: 1), wherein each internucleoside linkage of the oligonucleotide is a phosphorothioate linkage, each nucleoside of the oligonucleotide is a 2'- methoxyethyl (MOE) nucleoside, and each cytosine is a 5'-methylcytosine.
• SEQ ID NO: 1 is also known as BIIB058, and is described in WO2007/002390, WO2010/148249, and US8,980,853, the teaching of each are herein incorporated by reference.
• the target oligonucleotide separated by the method as described in either the first or second embodiment is a 5-10-5 MOE gapmer, having a sequence of (from 5' to 3')
• CAGGATACATTTCTACAGCT SEQ ID NO: 2
• each of nucleosides 1-5 and 16-20 are 2'-0-methoxyethylribose modified nucleosides
• each of nucleosides 6- 15 are 2'-deoxynucleosides
• internucleoside linkages between nucleosides 2 to 3, 4 to 5, 16 to 17, and 18 to 19 are phosphodiester linkages and the internucleoside linkages between nucleosides 1 to 2, 3 to 4, 5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10, 10 to 11, 11 to 12, 12 to 13, 13 to 14, 14 to 15, 15 to 16, 17 to 18, and 19 to 20 are phosphorothioate linkages, and wherein each cytosine is a 5'- methylcytosine.
• SEQ ID NO: 2 is described by the following chemical notation: mCes Aeo Ges Geo Aes Tds Ads mCds Ads Tds Tds Tds mCds Tds Ads mCeo Aes Geo mCes Te; wherein,
• A an adenine
• mC a 5'-methylcytosine
• G a guanine
• o a phosphodiester internucleoside linkage.
• SEQ ID NO: 2 is as known as BIIB067 or ISIS 666853 and is described in
• the hydrophobic adsorbent is any material to which the target oligonucleotide will bind such that it can be separated from the product-related impurities in the method as described in the first and second embodiments.
• the hydrophobic adsorbent include hydrophilic carbohydrates: cross-linked agarose and synthetic copolymer materials.
• the hydrophobic adsorbent comprises either phenyl, butyl or hexyl.
• Hexyl650C is a suitable hydrophobic adsorbent.
• the hydrophobic adsorbent is packed at a bed height of at least 15 cm, for example at least 20 cm, at least 25 cm, or at least 30 cm; or from about 15 cm to about 30 cm; from about 15 cm to 20 cm, from about 20 to about 25 cm, or about 25 cm to about 30 cm.
• the “dynamic loading capacity” is defined as the amount of product (e.g. ,
• oligonucleotide product that will bind to a chromatography resin under typical flow conditions and is determined under specific flow conditions and the loading salt
• the concentration is calculated based on the amount that can be loaded before product levels are measured in the flow through (referred to as the "breakthrough point").
• the material to be separated is applied to the resin in a flowing fashion (as opposed to static done in a batch mode) at a particular flow rate, for example, about 100 to about 250 cm/hr, and in particular, 200 cm/hr.
• a particular flow rate for example, about 100 to about 250 cm/hr, and in particular, 200 cm/hr.
• One of skill in the art would know how to select both the salt concentration based on the product's solubility in that salt and the flow rate based on the bead size, bed height and other variables such that the inlet pressure is not exceeded to achieve a particular dynamic loading ratio.
• a hydrophobic adsorbent for the oligonucleotide mixture is 50 mg/mL (dynamic)
• application of 50 mg/mL of the mixture would be at 100 % dynamic loading capacity.
• application of 25 mg/mL of the mixture would be at 50 % dynamic loading capacity.
• the dynamic loading capacity is about 32 % to about 78 %, for example, about 32 % to about 45%, about 40% to about 50%, about 45 % to about 55%, about 50% to about 60%, about 55 % to about 65 %, about 60 to about 70%, about 65% to about 78%, or about 32% to about 50 %, about 40 to about 75%, or about 50% to about 78%.
• the dynamic loading capacity is about 40 % to about 100 %, for example, about 40 % to about 50%, about 50% to about 60%, about 60 % to about 70%, about 70% to about 80%, about 80 % to about 90 %, about 90 to about 100%, about 40% to about 75%, or about 40% to about 60 %, or about 40% to about 80%.
• the dynamic loading capacity is about 40 % to about 78 %, for example, about 40 % to about 45%, about 45% to about 50%, about 50 % to about 55%, about 55% to about 60%, about 60 % to about 65 %, about 65 to about 70%, about 70% to about 75%, or about 40% to about 50 %, about 40 to about 75%, or about 50% to about 78%.
• the method is as described for either the first or second embodiment, and salt is added to the mixture as aqueous salt solution or the salt is dissolved directly into the mixture.
• the salt includes any cation of NH 4 + , K + or Na + and any anion comprised of F - " , [S0 4 ] - ⁇ 2 , [HP0 4 ] - ⁇ 2 , acetate or CI " or combinations thereof.
• the salt is ammonium sulfate.
• the method is as described for any of the first, second, or third embodiments, wherein the flow rate of the wash step is slower than the loading flow rate.
• the flow rate of the loading step is from about 150 cm/hr to about 250 cm/hr and the flow rate of the wash step is from about 50 cm/hr to about 150 cm/hr, for example, the flow rate of the loading step is from about 175 cm/hr to about 225 cm/hr and the flow rate of the wash step is from about 75 cm/hr to about 125 cm/hr.
• the flow rate of the loading step is from about 200 cm/hr and the flow rate of the wash step is from about 100 cm/hr.
• the eluting solution is selected from water, an aqueous salt solution, ethylene glycol, or propylene glycol or mixtures thereof.
• the salt includes any cation of NH 4 + , K + or Na + and any anion comprised of F, [S0 4 ] ⁇ 2 , [HP0 4 ] ⁇ 2 , acetate or CI " or combinations thereof.
• the salt is ammonium sulfate.
• the method is as described for any of the first, second, third, fourth, or fifth embodiments, wherein the elution collection is delayed such that it does not include the first 2-25%, the first 2-10%, the first 2-8%, the first 4-6%, the first 5-10% or the first 10 - 25% of the product elution peak.
• the collection is delayed such that it does not include the first 5% of the product elution peak.
• the eluent is collected in fractions and the fraction size is adjusted to separate the target oligonucleotide from the product-related impurities in separate fractions.
• the fraction size can be readily determined by a skilled person in the art, depending partly on the difference in elution time between the oligonucleotide and the product-related impurity, the amount of the crude product containing the target oligonucleotide and the product-related impurities to be separated, etc.
• the method is as described for any of the first, second, third, fourth, or fifth embodiments, wherein the elution collection does not include the first and the last 2-25% of the product elution peak. More specifically, the elution collection does not include the first and the last 2-10%, the first and the last 2-8%, the first and the last 4-6%, the first and the last 5- 10 % or the first and the last 10-25 % of the product elution peak. In another specific embodiment, the elution collection doe not include the first and the last 5% of the product elution peak.
• the wash solution is kept constant during the wash step, known as isocratic wash mode.
• the washing solution is varied during the wash step, known as gradient wash mode.
• the wash solution can be varied from high ionic strength or polarity to low ionic strength or polarity.
• the decrease in polarity or ionic strength can be achieved by decreasing the salt concentration of the aqueous solution or increasing the volume ratio of the more polar solvent, e.g. , water, or other polar solvents, e.g. , ethylene or propylene glycol to the higher salt solution.
• the wash solution can be varied from low polarity or high ionic strength to high polarity or low ionic strength.
• a gradient wash step can be followed by an isocratic wash step, or vice versa.
• the eluting solution is kept constant during the elution, known as isocratic elution mode.
• the eluting solution is varied during elution, known as gradient elution mode.
• the eluting solution can be varied from high ionic strength or low polarity to low ionic strength or high polarity.
• the increase in polarity or decrease in ionic strength can be achieved by decreasing the salt concentration of the aqueous solution or increasing the volume ratio of the more polar solvent, e.g., water, or other polar solvent, e.g., ethylene or propylene glycol to the higher salt solution.
• the elution solution can be varied from low polarity or high ionic strength to high polarity or low ionic strength.
• a gradient elution can be followed by an isocratic elution, or vice versa.
• the method of the present invention described herein can also remove EEI and/or LEI.
• Product Dilution buffer 850mM ammonium sulfate, 50mM tris, pH 8.5
• Equilibration buffer 800mM ammonium sulfate, 50mM tris, pH 8.5
• Wash buffer 440mM ammonium sulfate, 50mM tris, pH 8.5
• Elution buffer 40mM ammonium sulfate, 50mM tris, pH 8.5
• sample SEQ ID NO: 2
• dilution buffer final ammonium sulfate concentration is 765mM
• the column was washed with 7 CVs of 440mM ammonium sulfate, 50mM tris, pH 8.5 at lOOcm/hr.
• the column was eluted with 6CVs of 40mM ammonium sulfate, 50mM tris, pH 8.5 at 200cm/hr.
• the column was stripped with 2 CVs of deionized water at 200cm/hr.
• the column was column was cleaned with 3 CVs of IN sodium hydroxide at 200cm/hr and stored in 3 CVs of 0.1N sodium hydroxide at 200cm/hr.
• Product Dilution buffer 850mM ammonium sulfate, 50mM tris, pH 8.5
• Equilibration buffer 800mM ammonium sulfate, 50mM tris, pH 8.5
• Wash buffers 440mM ammonium sulfate, 50mM Tris, pH 8.5
• Elution buffer 40mM ammonium sulfate, 50mM Tris, pH 8.5
• sample SEQ ID NO: 2
• dilution buffer final ammonium sulfate concentration is 765mM
• the column was washed at lOOcm/hr with the specified wash buffer and CVs in Table 3.
• the column was eluted at 200cm/hr with the specified elution buffer and CVs in Table 3.
• the column was stripped with 2 CVs of deionized water at 200cm/hr.
• the column was column was cleaned with 3 CVs of IN sodium hydroxide at 200cm/hr. and stored in 3 CVs of 0.1N sodium hydroxide at 200cm/hr.
• Product Dilution buffer 575mM ammonium sulfate, 50mM tris, pH 8.5
• Equilibration buffer 500mM ammonium sulfate, 50mM tris, pH 8.5
• Wash buffer 250mM ammonium sulfate, 50mM tris, pH 8.5
• Elution buffer lOmM ammonium sulfate, 50mM tris, pH 8.5
• the column was washed with 7 CVs of 250mM ammonium sulfate, 50mM tris, pH 8.5 at 75cm/hr.
• the column was eluted with 9CVs of lOmM ammonium sulfate, 50mM tris, pH 8.5 at 150cm/hr and the peak was collected.
• the column was stripped with 3 CVs of deionized water at 150cm/hr.
• the column was column was cleaned with 3 CVs of IN sodium hydroxide at 150cm/hr and stored in 3 CVs of 0.1N sodium hydroxide at 150cm/hr.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Biochemistry (AREA)
• Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Analytical Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Saccharide Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (15)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=59216016

Family Applications (1)

Country Status (12)

Cited By (7)

Families Citing this family (11)

Citations (10)

Family Cites Families (9)

• 2017
  • 2017-06-13 BR BR112018075667-9A patent/BR112018075667B1/pt active IP Right Grant
  • 2017-06-13 NZ NZ749360A patent/NZ749360A/en unknown
  • 2017-06-13 EP EP17733243.4A patent/EP3468981B1/en active Active
  • 2017-06-13 JP JP2018565677A patent/JP7075359B2/ja active Active
  • 2017-06-13 WO PCT/US2017/037126 patent/WO2017218454A1/en not_active Ceased
  • 2017-06-13 ES ES17733243T patent/ES2988362T3/es active Active
  • 2017-06-13 MX MX2018015654A patent/MX2018015654A/es unknown
  • 2017-06-13 AU AU2017284202A patent/AU2017284202B2/en active Active
  • 2017-06-13 KR KR1020197000396A patent/KR102461234B1/ko active Active
  • 2017-06-13 US US16/309,622 patent/US10947262B2/en active Active
  • 2017-06-13 CN CN201780037028.4A patent/CN109641928B/zh active Active
• 2018
  • 2018-12-11 IL IL263639A patent/IL263639B/en unknown
• 2021
  • 2021-03-12 US US17/199,921 patent/US20210269467A1/en not_active Abandoned
• 2024
  • 2024-06-13 US US18/742,011 patent/US20250011357A1/en active Pending

Patent Citations (11)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events